Additional Information
Market: AIM
Sector: Chemicals
EPIC: TYR
Latest Price: 3.25p  (-7.14% Descending)
52-week High: 38.00p
52-week Low: 3.25p
Market Cap: 3.12M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
TyraTech Inc.
www.tyratech.com

TyraTech Nature's Technology effectively controls insects and parasites while providing a new level of safety for people, animals and the environment. TyraTech's patented scientific process targets receptors active only in invertebrates, not in humans or animals. TyraTech leverages this scientific platform to develop natural products that are as effective as traditional chemical options.

Pdf

TyraTech wins latest round in Molecular Securities case

26th Oct 2011, 7:26 am by Jon Mainwaring TyraTech’s products are based on natural ingredients and used mainly as pesticides

Natural pesticides business TyraTech (LON:TYR) announced this morning that it has won the latest round in a legal case the firm is involved in with Molecular Securities Incorporated.

TyraTech said that the State of New York Court of Appeals issued a decision on Octover 20 that denies Molecular’s request to appeal the May 26 2011 ruling by the New York Supreme Court in favour of TyraTech and against Molecular. This decision dismissed Molecular’s complaint in its entirety.

In November 2008, Molecular filed a complaint against TyraTech asserting claims for breach of contract and quantum merit. Molecular claimed it was owed US$2,760,470 for services it said it provided to TyraTech, as well as interest, lawyers’ fees and costs.

TyraTech said that it believes the Court of Appeals ruling will bring to an end any further litigation against the firm.

Yesterday, TyraTech announced that it had engaged Destum Partners, a US-based biopharmaceutical consultancy to assist it in seeking suitable partners for TyraTech’s natural head lice product. TyraTech’s head lice product uses its ‘Nature’s Technology’ approach and represents the firm’s first product entry in the personal health care market. The firm’s patented formulation uses combinations of natural plant oils.


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.